256 related articles for article (PubMed ID: 10590286)
1. In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans.
Hossain MA; Maesaki S; Mitsutake K; Kakeya H; Sasaki E; Tomono K; Tashiro T; Kohno S
J Antimicrob Chemother; 1999 Dec; 44(6):827-9. PubMed ID: 10590286
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.
Perfect JR; Cox GM; Dodge RK; Schell WA
Antimicrob Agents Chemother; 1996 Aug; 40(8):1910-3. PubMed ID: 8843302
[TBL] [Abstract][Full Text] [Related]
3. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Caselli F; Giannini D; Camiletti V; Fileni B; Giacometti A; Di Francesco LF; Scalise G
J Antimicrob Chemother; 2001 Dec; 48(6):769-73. PubMed ID: 11733459
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
Nishikawa H; Fukuda Y; Mitsuyama J; Tashiro M; Tanaka A; Takazono T; Saijo T; Yamamoto K; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Kohno S; Izumikawa K
J Antimicrob Chemother; 2017 Jun; 72(6):1709-1713. PubMed ID: 28201509
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592).
Yildiran ST; Fothergill AW; Sutton DA; Rinaldi MG
Mycoses; 2002 Nov; 45(9-10):378-83. PubMed ID: 12421285
[TBL] [Abstract][Full Text] [Related]
6. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
[TBL] [Abstract][Full Text] [Related]
7. New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformans
Lu RY; Ni TJ; Wu J; Yan L; Lv QZ; Li LP; Zhang DZ; Jiang YY
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31791946
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole.
Yildiran ST; Saracli MA; Fothergill AW; Rinaldi MG
Eur J Clin Microbiol Infect Dis; 2000 Apr; 19(4):317-9. PubMed ID: 10834825
[TBL] [Abstract][Full Text] [Related]
9. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
[TBL] [Abstract][Full Text] [Related]
10. Interactions of posaconazole and flucytosine against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Najvar LK; Bocanegra R; Caselli F; Di Cesare S; Giannini D; Di Francesco LF; Giacometti A; Carle F; Scalise G; Graybill JR
Antimicrob Agents Chemother; 2001 May; 45(5):1355-9. PubMed ID: 11302795
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.
Hata K; Kimura J; Miki H; Toyosawa T; Moriyama M; Katsu K
Antimicrob Agents Chemother; 1996 Oct; 40(10):2243-7. PubMed ID: 8891122
[TBL] [Abstract][Full Text] [Related]
12. Voriconazole, combined with amphotericin B, in the treatment for pulmonary cryptococcosis caused by C. neoformans (serotype A) in mice with severe combined immunodeficiency (SCID).
Silva EG; Paula CR; de Assis Baroni F; Gambale W
Mycopathologia; 2012 Jun; 173(5-6):445-9. PubMed ID: 22071662
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
Schwarz P; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
[TBL] [Abstract][Full Text] [Related]
14. Activity of sertraline against Cryptococcus neoformans: in vitro and in vivo assays.
Treviño-Rangel Rde J; Villanueva-Lozano H; Hernández-Rodríguez P; Martínez-Reséndez MF; García-Juárez J; Rodríguez-Rocha H; González GM
Med Mycol; 2016 Mar; 54(3):280-6. PubMed ID: 26705833
[TBL] [Abstract][Full Text] [Related]
15. [Pulmonary cryptococcosis treated by combination therapy of fluconazole plus flucytosine].
Tanaka K; Kohno S; Maesaki S; Mitsutake K; Miyazaki H; Miyazaki T; Tomono K; Kaku M; Koga H; Hara K
Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31(12):1528-33. PubMed ID: 8121088
[TBL] [Abstract][Full Text] [Related]
16. Tissue distribution and antifungal effect of liposomal itraconazole in experimental cryptococcosis and pulmonary aspergillosis.
Le Conte P; Joly V; Saint-Julien L; Gillardin JM; Carbon C; Yeni P
Am Rev Respir Dis; 1992 Feb; 145(2 Pt 1):424-9. PubMed ID: 1310577
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of Cryptococcus neoformans isolates to five antifungal drugs using a colorimetric system and the reference microbroth method.
López-Jodra O; Torres-Rodríguez JM; Méndez-Vásquez R; Ribas-Forcadell E; Morera-López Y; Baró-Tomás T; Alia-Aponte C
J Antimicrob Chemother; 2000 May; 45(5):645-9. PubMed ID: 10797087
[TBL] [Abstract][Full Text] [Related]
18. Antifungal activity of D0870 against murine infections and its mechanism of action.
Yamada H; Tsuda T; Watanabe T; Kusakabe S; Mochizuki H
Chemotherapy; 1998; 44(2):112-20. PubMed ID: 9551242
[TBL] [Abstract][Full Text] [Related]
19. Turbidimetric and visual criteria for in vitro susceptibility testing of Cryptococcus neoformans clinical isolates.
Del Poeta M; Barchiesi F; Arzeni D; Marinucci G; Scalise G
Mycoses; 1994; 37(11-12):411-6. PubMed ID: 7659128
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
